Anuradha Banerjee

Hematology | Oncology
1825 4th St Fl 6
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

PNOC009: Convection-enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine glioma.

PNOC009: Convection-enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine glioma.

Journal: Neuro-oncology advances
Published: June 27, 2025

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

Journal: Neuro-oncology
Published: April 17, 2025

Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).

Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 12, 2022

Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.

Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.

Journal: Acta neuropathologica
Published: July 11, 2022

Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.

Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.

Journal: Neuro-oncology
Published: March 21, 2022

Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.

Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.

Journal: Ophthalmology
Published: September 07, 2019

Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma.

Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma.

Journal: Acta neuropathologica
Published: February 08, 2019

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Journal: The Lancet. Oncology
Published: February 06, 2019

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.

Journal: Acta neuropathologica communications
Published: September 11, 2018

The genetic landscape of gliomas arising after therapeutic radiation.

The genetic landscape of gliomas arising after therapeutic radiation.

Journal: Acta neuropathologica
Published: July 27, 2018

The genetic landscape of ganglioglioma.

The genetic landscape of ganglioglioma.

Journal: Acta neuropathologica communications
Published: May 26, 2018

Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.

Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.

Journal: Journal of neuro-oncology
Published: May 14, 2018
Showing 1-12 of 23

Last Updated: 09/26/2026